AIMS: The influence of nanoencapsulation of mometasone furoate (MF) in poly(ε-caprolactone) lipid-core nanocapsules (LNC) on its in vitro human skin permeation and penetration was evaluated. METHODS: Semisolid formulations were prepared by increasing the viscosity of LNC using a carbomer (Carbopol(®) Ultrez at 0.5% w/v). Two complementary techniques (the static Franz diffusion cell model and the Saarbrücken penetration model) were used to evaluate skin permeation/penetration. RESULTS: The drug release rate was decreased by nanoencapsulation. The skin permeability of MF was controlled by the nanoencapsulation as well as by increasing the viscosity. Furthermore, the formulation containing the nanoencapsulated MF controlled the amount of drug reaching the deeper skin layers without changing its accumulation in the stratum corneum. CONCLUSION: This formulation is suitable for prolonged treatment of skin disorders which should avoid systemic absorption.
AIMS: The influence of nanoencapsulation of mometasone furoate (MF) in poly(ε-caprolactone) lipid-core nanocapsules (LNC) on its in vitro human skin permeation and penetration was evaluated. METHODS: Semisolid formulations were prepared by increasing the viscosity of LNC using a carbomer (Carbopol(®) Ultrez at 0.5% w/v). Two complementary techniques (the static Franz diffusion cell model and the Saarbrücken penetration model) were used to evaluate skin permeation/penetration. RESULTS: The drug release rate was decreased by nanoencapsulation. The skin permeability of MF was controlled by the nanoencapsulation as well as by increasing the viscosity. Furthermore, the formulation containing the nanoencapsulated MF controlled the amount of drug reaching the deeper skin layers without changing its accumulation in the stratum corneum. CONCLUSION: This formulation is suitable for prolonged treatment of skin disorders which should avoid systemic absorption.
Authors: Juan J Carreras; Willian E Tapia-Ramirez; Adrian Sala; Antonio J Guillot; Teresa M Garrigues; Ana Melero Journal: Drug Deliv Transl Res Date: 2020-04 Impact factor: 4.617
Authors: Antonio J Guillot; Dimitris Petalas; Pari Skondra; Hortensia Rico; Teresa M Garrigues; Ana Melero Journal: Drug Deliv Transl Res Date: 2021-02-02 Impact factor: 4.617
Authors: Antonio José Guillot; Enrique Jornet-Mollá; Natalia Landsberg; Carmen Milián-Guimerá; M Carmen Montesinos; Teresa M Garrigues; Ana Melero Journal: Pharmaceutics Date: 2021-03-20 Impact factor: 6.321